Madrigal Pharmaceuticals公布的最新研究数据显示,其药物Rezdiffra在治疗代谢功能障碍相关脂肪性肝炎(MASH)患者时,能够有效降低与心血管疾病及肝脏损伤相关的风险标志物水平。这一发现进一步支持了Rezdiffra在改善MASH患者长期健康结局方面的潜在价值。
Madrigal Pharmaceuticals公布的最新研究数据显示,其药物Rezdiffra在治疗代谢功能障碍相关脂肪性肝炎(MASH)患者时,能够有效降低与心血管疾病及肝脏损伤相关的风险标志物水平。这一发现进一步支持了Rezdiffra在改善MASH患者长期健康结局方面的潜在价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.